Roivant Sciences Ltd. - Common Shares (ROIV)

Roivant (ROIV) Q4 2025 Earnings Transcript

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in d

This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.

Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.

The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that have fundamentally reshaped the competitive landscape for autoimmune treatments. As of April 2, 2026, Roivant has reached a multi-year valuation peak,

This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.

In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant Sciences and Arbutus Biopharma (NASDAQ:ABUS). Announced on March 3, 2026, the deal concludes one of the most contentious patent

BlackBarn Capital has raised its investment in Warby Parker, a direct-to-consumer eyewear brand recognized for its affordable frames and expanding network of stores. As Warby Parker opens more locations and adds vision services, investors are paying attention to whether its strong brand can drive lasting growth.

The news is likely to come as a relief to many investors, Citi told investors in a research note.

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines.

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.

This audio and imaging technology provider licenses Dolby Atmos and Vision to global entertainment and device markets.

TTM Technologies supplies advanced printed circuit boards and RF components for high-reliability applications across diverse industries.

American Healthcare REIT manages a diverse portfolio of healthcare properties across the U.S. and U.K., serving institutional tenants.

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a significant 15% stock surge, a move driven by clinical validation of its diversified "Vant" model. This recent rally—pushing shares toward a yearly high of $24.21—is primarily [...]

In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500. This rally, which reached its zenith on January 22, 2026, represents the longest period of small-cap dominance since

Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.